Fig. 3From: A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancerKaplan-Meier estimates of progression-free survival of patients with L858R and ex19del EGFR mutations (A) patients starting sequential regimen; (B) patients starting up-front combinationBack to article page